FINWIRES · TerminalLIVE
FINWIRES

$AZN

28 stories mentioning AZN

Every FINWIRES story that references AZN, newest first.

Sectors

Sector Update: Health Care Stocks Softer in Afternoon Trading

Health care stocks declined Wednesday afternoon, with the NYSE Health Care Index down 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.9%.The iShares Biotechnology ETF (IBB) fell 2%.In corporate news, AbbVie (ABBV) raised its full-year outlook on Wednesday as the biopharmaceutical company recorded better-than-expected Q1 results, driven by robust revenue growth from its Skyrizi and Rinvoq immunology drugs. Its shares rose 3.4%.AstraZeneca (AZN) will invest 300 million pounds ($404.9 million) in the UK, focusing on its sites in Cambridge and Macclesfield, in a move aimed at boosting the country's life sciences sector, Bloomberg reported. AstraZeneca shares were down 1.2%.KalVista Pharmaceuticals (KALV) and Chiesi Group said Wednesday they have signed an agreement through which Chiesi will buy KalVista for $27 per share in cash, or about $1.9 billion. KalVista shares surged nearly 39%.

$ABBV$AZN$KALV
Wire

Market Chatter: AstraZeneca to Invest $405 Million in UK Sites

AstraZeneca (AZN) will invest 300 million pounds ($404.9 million) in the UK, focusing on its sites in Cambridge and Macclesfield, in a move aimed at boosting the country's life sciences sector, Bloomberg reported Wednesday.The investment will fund expansion at AstraZeneca's Cambridge biomedical campus and boost manufacturing and research capabilities at its Macclesfield site, according to the report.In a statement to, AstraZeneca CEO Pascal Soriot praised the UK government for its efforts to "improve access for patients, including four new approvals since the beginning of the year across the UK." He said the company is looking forward to "further enhancing the access and the reimbursement environment and build a strong life sciences sector."Soriot said AstraZeneca is "investing a total of 300 million pounds in the UK, which includes investment in our Macclesfield site, including a lab of the future that will use digital and data tools to advance drug development."Shares of AstraZeneca were down 2.3% in US trading on Wednesday.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $183.67, Change: $-3.07, Percent Change: -1.64%

$AZN
Sectors

Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday

Health care stocks were mixed pre-bell Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.4% lower and the iShares Biotechnology ETF (IBB) up 0.1%.Teva Pharmaceutical Industries (TEVA) shares were up more than 8% after the company posted higher Q1 non-GAAP earnings and net revenue.AstraZeneca (AZN) stock was down more than 1% even after the company reported higher Q1 core earnings and revenue.GE Healthcare Technologies (GEHC) shares were down more than 9% after the company posted a decline in Q1 adjusted earnings, and cut its 2026 adjusted EPS outlook.

$AZN$GEHC$IBB$TEVA$XLV
Research

Research Alert: Azn Q1 2026 Beat As Oncology Remains Strong; Reaffirms 2026 Guidance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:AstraZeneca (AZN) posted 13% total revenue growth (+8% at constant exchange rates, CER) to USD15.3B in Q1 2026, beating consensus estimates of USD14.9B, with oncology remaining the key contributor (+16% CER). Imfinzi climbed 30% CER, supported by multiple new launches, while Enhertu grew 34% CER on continued global demand, with core operating margin remaining broadly stable Y/Y at 35% despite R&D (+8% CER) and SG&A (+7% CER) expense increases. We continue to like AZN for its strong pipeline and numerous key data readouts throughout 2026, supported by four positive Phase 3 trials and 14 regulatory approvals achieved since Q4 2025. AZN reiterated its 2026 guidance for mid- to high-single-digit revenue growth and low double-digit core EPS growth, with currency movements expected to provide modest support. We see this compelling dataset helping support its ambitious target to reach USD80B in total revenue by 2030, with guidance that is more favorable than peers like Novartis.

$AZN
Sectors

Sector Update: Health Care Stocks Lean Lower Premarket Monday

Health care stocks were leaning lower premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) declining by 0.4% and the iShares Biotechnology ETF (IBB) down 0.5%.Biogen (BIIB) has agreed to acquire TJ Biopharma's rights to the felzartamab antibody in the Greater China Region under a definitive agreement, the companies said. Biogen shares were up more than 1% pre-bell.AstraZeneca (AZN) said its pivotal phase 3 study of tozorakimab demonstrated a "significant" reduction in the annual rate of moderate-to-severe chronic obstructive pulmonary disease, or COPD, exacerbations in trial participants. Shares of AstraZeneca were down more than 1% premarket.ANI Pharmaceuticals (ANIP) stock was up more than 1% after the company said it has received US Food and Drug Administration approval and launched Pimozide Tablets in 1 mg and 2 mg doses, the generic version of Orap, with 180-day Competitive Generic Therapy exclusivity.

$ANIP$AZN$BIIB$IBB$XLV
Commodities

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday as Oil Prices Rise on Renewed Middle East Tensions

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.4% and the actively traded Invesco QQQ Trust (QQQ) was 0.4% lower in Monday's premarket activity as rising oil prices tied to renewed Middle East tensions weigh on sentiment.US stock futures were also lower, with S&P 500 Index futures down 0.5%, Dow Jones Industrial Average futures slipping 0.5%, and Nasdaq futures retreating 0.4% before the start of regular trading.No economic releases are on Monday's schedule.In premarket activity, bitcoin was up by 0.4%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 2.8% lower, Ether ETF (EETH) fell by 4.8%, and Bitcoin & Ether Market Cap Weight ETF (BETH) gained 1.7%.Power Play:IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) retreated 0.2%, while the Vanguard Industrials Index Fund (VIS) fell 1.6% and the iShares US Industrials ETF (IYJ) was inactive.TopBuild (BLD) stock was up more than 2% before the opening bell, while QXO (QXO) shares declined by 2% after QXO agreed to acquire TopBuild for $505 per share in a deal valued at about $17 billion.Winners and Losers:TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) retreated 0.5%, and the iShares US Technology ETF (IYW) was 0.3% lower, while the iShares Expanded Tech Sector ETF (IGM) was down 0.9%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) was 0.1% lower, while the iShares Semiconductor ETF (SOXX) decreased by 0.2%.AST SpaceMobile (ASTS) shares were down more than 12% in Monday's premarket activity after the company said Sunday the BlueBird 7 satellite was placed into a lower-than-planned orbit during the New Glenn 3 mission and will be de-orbited.Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) retreated 0.3%, the Vanguard Health Care Index Fund (VHT) retreated 0.4%, while the iShares US Healthcare ETF (IYH) gained 0.1%. The iShares Biotechnology ETF (IBB) was down 0.6%.AstraZeneca (AZN) stock was down more than 2% premarket, after a 2.2% gain at Friday's close. The company said Monday its pivotal phase 3 study of tozorakimab demonstrated a "significant" reduction in the annual rate of moderate-to-severe COPD exacerbations in trial participants.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) retreated 0.5%. Direxion Daily Financial Bull 3X Shares (FAS) was down 1.4%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 1.7% higher.Bank of Hawaii (BOH) shares were down more than 2% pre-bell after the company reported lower-than-expected Q1 earnings and revenue.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was down 0.2%, while the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was up 1.1%. The iShares US Consumer Staples ETF (IYK) rose 2.3%. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) lost 0.7%. The VanEck Retail ETF (RTH) was inactive, while the State Street SPDR S&P Retail ETF (XRT) retreated by 0.5%.Toyota Motor (TM) shares were down more than 1% pre-bell, after closing Friday with a 2% rise. Reuters reported Monday that Toyota Tsusho and Indonesian state energy firm Pertamina's renewable energy unit are in talks over a potential $200 million to $300 million joint investment for a bioethanol production facility in Indonesia's Lampung province.EnergyThe iShares US Energy ETF (IYE) was 1.3% higher, while the State Street Energy Select Sector SPDR ETF (XLE) was up by 1.1%.Eni (E) stock was up more than 1% before the opening bell after the company said it made a gas discovery in the Kutei Basin off the coast of Indonesia.CommoditiesFront-month US West Texas Intermediate crude oil rose by 5.6% to $88.52 per barrel on the New York Mercantile Exchange. Natural gas advanced by 2.1% to $2.73 per 1 million British Thermal Units. The United States Oil Fund (USO) increased by 4.9%, while the United States Natural Gas Fund (UNG) was 1.1% higher.Gold futures for May were down by 1% at $4,830.50 an ounce on the Comex. Silver futures retreated by 2.4% to $80.47 an ounce. SPDR Gold Shares (GLD) was 0.9% lower, and the iShares Silver Trust (SLV) fell by 2%.

Dow JonesNasdaq CompositeS&P 500$ASTS$AZN$BETH$BITO$BLD$BOH$E$EEM$EETH$EXI$FAS$FAZ$GLD$IBB$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$PMR$QQQ$QXO$RTH$SLV$SOXX$SPY$TM$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Wire

AIM ImmunoTech Starts Late-Stage Trial of Ampligen in Pancreatic Cancer

AIM ImmunoTech (AIM) said Thursday it has begun a phase 3 clinical trial of its experimental drug Ampligen for pancreatic cancer, calling the move an important milestone supported by encouraging phase 2 results.The company recently signed an agreement with Thermo Fisher Scientific's (TMO) PPD clinical research unit to help design the phase 3 study.An ongoing phase 2 trial testing Ampligen with AstraZeneca's (AZN) immunotherapy durvalumab has shown early signs of improved progression-free survival and overall survival, along with a favorable safety profile, AIM said.Price: $0.57, Change: $+0.03, Percent Change: +5.35%

$AIM$AZN$TMO
Asia Markets

European Equities Traded in the US as American Depositary Receipts Trending Lower in Wednesday Trading

European equities traded in the US as American depositary receipts were heading lower late Wednesday morning, declining 0.54% to 1,835.78 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by medical device maker EDAP TMS (EDAP) and biopharmaceutical firm Grifols (GRFS), which advanced 3% and 2.6%, respectively. They were followed by software company SAP (SAP) and biopharmaceutical company argenx (ARGX), which increased 2.5% each.The decliners from continental Europe were led by furniture maker Natuzzi (NTZ) and telecommunications company Nokia (NOK), which dropped 4.2% and 1.6%, respectively. They were followed by telecommunications company Ericsson (ERIC) and petroleum refiner Equinor (EQNR), which lost 1.5% and 1.2%, respectively.The gainers from the UK were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and software company Endava (DAVA), which rose 3.2% each. They were followed by biopharmaceutical companies Amarin (AMRN) and NuCana (NCNA), which were up 3% and 2.3% respectively.The decliners from the UK and Ireland were led by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company Mereo BioPharma Group (MREO), which fell 2.9% and 2.6% respectively. They were followed by pharmaceutical company AstraZeneca (AZN) and utilities company National Grid (NGG), which were down 1.3% and 1.2% respectively.

$AMRN$ARGX$AZN$DAVCA$EDAP$EQNR$ERIC$GRFS$MREO$NCNA$NGG$NOK$NTZ$SAP$TRIB$VDRZ

Showing 21-28 of 28

AZN News | FINWIRES